Pharmaceutical

AstraZeneca mulls risk strategy for Ultomiris following FDA response letter

The US FDA has requested that AstraZeneca make modifications to the Ultomiris REMS programme to approve a label expansion.

Sep 7, 2023 - 20:00
AstraZeneca mulls risk strategy for Ultomiris following FDA response letter
The US FDA has requested that AstraZeneca make modifications to the Ultomiris REMS programme to approve a label expansion.
Read the original article

Tags:

Previous Article

Signal: Nimbus raises $210m to foster drug discovery plans

Next Article

Idorsia reacquires aprocitentan rights from Janssen for $343m

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

STAT+: Vertex pain drug results met with measured optimism — and questions — by observers and experts

STAT+: Vertex pain drug results met with measured optim...

Jan 30, 2024

Sen. Elizabeth Warren probes abortion access amid states’ patchwork plans

Sen. Elizabeth Warren probes abortion access amid state...

May 31, 2023

Parenteral Solutions in Contract Manufacturing for the Pharmaceutical Industry 

Parenteral Solutions in Contract Manufacturing for the ...

Oct 16, 2024